PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)

$0.0071 -0.001 (-12.3457%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 72

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) News Sources

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

04-11-2025

yahoo.com

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

01-04-2026

yahoo.com

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

20-04-2026

yahoo.com

Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?

03-05-2026

yahoo.com

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

04-05-2026

yahoo.com

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

02-06-2026

yahoo.com

Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

10-06-2026

yahoo.com

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

16-06-2026

yahoo.com

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

30-06-2026

yahoo.com

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

08-07-2026

yahoo.com

PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) Sentiment Trend

0 25 50 75 100 75 74 67 90 67 66 75 60 62 83 04-11-2025 01-04-2026 20-04-2026 03-05-2026 04-05-2026 02-06-2026 10-06-2026 16-06-2026 30-06-2026 08-07-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) FAQs

toggle

What is the current price of PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)?

The current price of PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) is $0.0071.


toggle

PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) absolute price change since previous trading day?

The absolute price change of PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) since the previous trading day is $-0.001.


toggle

PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) percentage price change since previous trading day?

The percentage price change of PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) since the previous trading day is -12.3457%.


toggle

What is the most recent average sentiment score for PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)?

The most recent average sentiment score for PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) is 72 out of 100.


toggle

What is the most recent average sentiment for PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)?

The most recent sentiment for PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ) is .


SEC-8K** Filing Available For PASITHEA THERAPEUTICS -CW26 (KTTAW:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.